Umbrella Trial of Adjuvant Therapy in Completely Resected High-risk Stage IA-IB NSCLC: Focus on Driver Mutations

Exclusion Criteria

• •Evidence of unresectable/metastatic NSCLC, incomplete resection (R1/R2), or wedge resection only.
• •Prior systemic therapy (e.g., chemotherapy, targeted therapy, immunotherapy) for the current NSCLC.
• •Major surgery (excluding lung cancer surgery) within 3 weeks before first study dose.
• •Planned concurrent anti-cancer therapy (chemo, radiotherapy, or targeted therapy) during the study.
• •Clinically significant cardiac disorders (e.g., poorly controlled hypertension, recent MI or stroke, prolonged QTc).
• •History or suspicion of interstitial lung disease requiring treatment.
• •Active or uncontrolled infection (e.g., hepatitis B with detectable HBV DNA, hepatitis C, HIV, active TB).
• •Severe GI conditions impairing drug absorption (e.g., Crohn's, ulcerative colitis).
• •Use of strong CYP3A inducers/inhibitors within 1 week or ongoing need for warfarin.
• •Participation in another interventional trial within 4 weeks or receipt of a live vaccine within 180 days.
• •Any condition that may compromise adherence or safety, per investigator judgment.